• Avant Bio’s Q2 2026 market note flagged a widening premium for enabling technology in biopharma M&A and venture funding.
• Pharma dealmakers paid up for delivery platforms, highlighted by Lilly’s up-to-$7 billion Kelonia deal; Roche bought PathAI for $1.05 billion.
• The report put 2026 pharma M&A above $25 billion across 10 deals, led by infrastructure-style assets over drug programs.
• Venture investment reached about $4.1 billion despite fewer deals, falling to 132 from 203; Isomorphic’s $2.1 billion Series B drove concentration.
• Competitive advantage shifted toward proprietary biological datasets as AI tools commoditized; regulators increased scrutiny of AI in manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avant Bio LLC published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.